+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endocrine And Metabolic Disorders Drugs Market Research Reports

Endogenous Cushing's Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Endogenous Cushing's Syndrome - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Nephropathic Cystinosis - Pipeline Insight, 2025 - Product Thumbnail Image

Nephropathic Cystinosis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Antiphospholipid Syndrome (APS) - Pipeline Insight, 2025 - Product Thumbnail Image

Antiphospholipid Syndrome (APS) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Diabetic Kidney Disease (DKD) - Pipeline Insight, 2025 - Product Thumbnail Image

Diabetic Kidney Disease (DKD) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Diabetic Retinopathy - Pipeline Insight, 2025 - Product Thumbnail Image

Diabetic Retinopathy - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 180 Pages
  • Global
From
Gaucher's Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Gaucher's Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 50 Pages
  • Global
From
Hypogonadism- Pipeline Insight, 2025 - Product Thumbnail Image

Hypogonadism- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Hypoparathyroidism - Pipeline Insight, 2025 - Product Thumbnail Image

Hypoparathyroidism - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Osteoporosis - Pipeline Insight, 2025 - Product Thumbnail Image

Osteoporosis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Prediabetes - Pipeline Insight, 2025 - Product Thumbnail Image

Prediabetes - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Xlinked Hypophosphatemia (XLH) - Pipeline Insight, 2025 - Product Thumbnail Image

Xlinked Hypophosphatemia (XLH) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Severe Hypoglycemia - Pipeline Insight, 2025 - Product Thumbnail Image

Severe Hypoglycemia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Gout - Pipeline Insight, 2025 - Product Thumbnail Image

Gout - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Adult-onset Growth Hormone Deficiency - Pipeline Insight, 2025 - Product Thumbnail Image

Adult-onset Growth Hormone Deficiency - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Thyroid Hormone Receptor Agonists - Pipeline Insight, 2025 - Product Thumbnail Image

Thyroid Hormone Receptor Agonists - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Fibroblast Growth Factor 2 (FGFR2) - Pipeline Insight, 2025 - Product Thumbnail Image

Fibroblast Growth Factor 2 (FGFR2) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 90 Pages
  • Global
From
Dementia With Diabetes - Pipeline Insight, 2025 - Product Thumbnail Image

Dementia With Diabetes - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Chronic Pancreatitis - Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Pancreatitis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Congenital Hyperinsulinism - Pipeline Insight, 2025 - Product Thumbnail Image

Congenital Hyperinsulinism - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Central Precocious Puberty - Pipeline Insight, 2025 - Product Thumbnail Image

Central Precocious Puberty - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Loading Indicator

The Endocrine and Metabolic Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat endocrine and metabolic disorders. Endocrine disorders are conditions that affect the body's hormones, while metabolic disorders are conditions that affect the body's ability to process and use energy. Endocrine and metabolic disorders can include diabetes, thyroid disorders, obesity, and adrenal disorders. Endocrine and Metabolic Disorders Drugs are typically developed by pharmaceutical companies and are prescribed by physicians. These drugs can be used to treat a variety of endocrine and metabolic disorders, including diabetes, thyroid disorders, obesity, and adrenal disorders. Common drugs used to treat these conditions include insulin, metformin, and glucagon-like peptide-1 (GLP-1) agonists. Some of the major companies in the Endocrine and Metabolic Disorders Drugs market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. These companies are involved in the development, production, and marketing of drugs used to treat endocrine and metabolic disorders. Show Less Read more